Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Expenses (2016 - 2025)

Catalyst Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $90.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 14.93% year-over-year to $90.8 million; the TTM value through Dec 2025 reached $331.2 million, up 11.67%, while the annual FY2025 figure was $331.2 million, 11.67% up from the prior year.
  • Operating Expenses reached $90.8 million in Q4 2025 per CPRX's latest filing, up from $82.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $139.9 million in Q3 2023 to a low of $20.4 million in Q1 2021.
  • Average Operating Expenses over 5 years is $57.0 million, with a median of $60.7 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 335.18% in 2023, then plummeted 44.39% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $25.6 million in 2021, then grew by 17.17% to $30.0 million in 2022, then skyrocketed by 129.92% to $68.9 million in 2023, then increased by 14.67% to $79.0 million in 2024, then rose by 14.93% to $90.8 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Operating Expenses are $90.8 million (Q4 2025), $82.1 million (Q3 2025), and $80.3 million (Q2 2025).